



Mission: Our mission is to improve prostate cancer survival rates and patient care by providing clinical tools for individualized treatment decisions based on patient tumor biology.

Market Needs: Novel treatments for metastatic prostate cancer have been introduced in the clinic, but patient response varies, making individualized treatment necessary. Our research supports the classification of metastatic prostate cancer into subtypes that demonstrate differences in prognosis and tumor biology.

Innovative Clinical Tools: We are developing products to improve prostate cancer treatment:

Product 1: *Computational Pathology for Prognosis and Therapy Selection at Metastasis Diagnosis:* Product 1 is a non-invasive tool that uses digital image analysis of biomarkers in diagnostic biopsies to estimate patient response to conventional therapy for metastatic prostate cancer. We are conducting clinical studies to gather data and seeking partnerships and funding to further develop and test this tool.

Product 2: *Liquid Biopsy Analysis for Therapy Selection and Disease Monitoring:* Our liquid biopsy analysis estimates metastatic subtype and patient response to diverse treatments by measuring differentiating gene transcripts in CTCs isolated from blood plasma. It can be used to monitor treatment response and disease progression over time, enabling individualized therapies, and thereby improved patient outcomes.

Partnering with us and investing in our innovative clinical tools for metastatic prostate cancer will bring several benefits, including:

Improved patient outcomes: Our clinical tools allow for individualized treatment decisions based on patient tumor biology, leading to better patient care and longer patient survival.

Reduced healthcare costs: By optimizing therapy selection, we can reduce the risk of overtreatment and associated costs. This will result in benefits not only for the patients but also improve the profitability of healthcare providers.

Non-invasive methods: Our products are non-invasive, reducing patient discomfort and the need for invasive procedures. This makes them attractive to both patients and healthcare providers, increasing their adoption and market potential.

Innovative technology: Our use of computational pathology and liquid biopsy analysis represents the cutting edge of cancer diagnostics and treatment. By investing in our technology, you can be at the forefront of cancer research and innovation.

Significant market potential: Prostate cancer is a global public health concern with approximately 1.4 million new cases diagnosed every year worldwide. Our tools have the potential to transform the way metastatic prostate cancer is diagnosed and treated, making them highly attractive to potential investors and partners. By investing in our products, you can tap into a significant market opportunity.

CONTACT

Elin Thysell, Co-Founder, Chairman
+46 73 535 34 81
elin.thysell@ubicase.se

WEBSITE

www.phenotypediagnosics.com

INTELLECTUAL PROPERTY RIGHTS

Phenotype Diagnostics is currently working with several inventions of which two have status of submitted national patent applications.

MANAGEMENT & BOARD

Elin Thysell, Co-Founder, PhD, Umeå University
Pernilla Wikström, Co-Founder, Prof. Tumor biology, Umeå University
Anders Bergh, Co-Founder, MD, Prof. Pathology, Umeå University

ADVISORS

Andreas Josefsson, PhD, MD Urology, Umeå University Hospital
Camilla Thellenberg Karlsson, PhD, MD Oncology, Umeå University Hospital
Jonas Nilsson, PhD, expert liquid biopsies, Umeå University
Karin Welén, PhD, expert liquid biopsies, Gothenburg University
Peter Jacobsson, Business coach, Umeå Biotech Incubator
Andreas Lindberg, Business coach, Umeå Biotech Incubator

ABOUT US

Phenotype Diagnostics AB was established in 2021 with the goal of bringing cutting-edge academic research in prostate cancer diagnosis and treatment to the clinic. Our team of experts in pathology and tumor biology is dedicated to developing innovative solutions that improve patient outcomes.

CURRENT STATUS

We are currently focused on developing two independent products that have the potential to revolutionize the field of prostate cancer diagnosis and treatment.

We are seeking partners and investors with interest in improving prostate cancer treatment and care.

We are open to explore partnerships for computational pathology and liquid biopsy analysis, out-licensing opportunities, and sales as we work towards making these products available to the wider medical community.